山西嘉源生物医药

Shanxi Jiayuan Biological Medicine is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs for pain management and neurological disorders. The company's primary focus is on developing highly selective sodium channel blockers, specifically targeting Nav1.7 and Nav1.8, to provide non-opioid alternatives for chronic and acute pain. Their lead candidate, JY001, is an orally bioavailable Nav1.7 inhibitor designed to treat conditions such as erythromelalgia and diabetic peripheral neuropathy. Jiayuan Biological Medicine operates out of Shanxi Province and maintains a research facility dedicated to medicinal chemistry and clinical development.